We highlight one medical center's experiences with primary malignancies of
the small bowel. During a 27-year period, 79 patients were treated fur smal
l bowel tumors. Of these, 15 (20%) were lost to follow-up; thus, 61 patient
s were reviewed retrospectively with emphasis on histological distribution
and their topography, perioperative complications, overall survival, and pr
ognostic factors. In our 63-patient series, 33 (51.6%) presented with adeno
carcinoma; 10 (15.5%), lymphoma; 8 (12.1%), leiomyosarcoma; 5 (7.6%), neuro
genic tumor; 2 (3%), unclassified carcinoma; 5 (7.6%), other types of sarco
ma; and 1 patient presented with synchronous adenocarcinoma and lymphoma. O
f all patients, 30 (46.9%) were curatively treated, whereas 34 (53.1%) unde
rwent palliative procedures. Hospital lethality was 9.4% and mainly occurre
d in patients operated on under emergency circumstances. Reoperation rate w
as 29.7%. The observation period lasted at least five years or until death;
three patients were alive less than five years postoperatively. Cumulative
five-year survival rate was 22.5% in the adenocarcinoma group, 33.3% in th
e: lymphoma group, 33.3% in the leiomyosarcoma group, and 22.2% in patients
with other tumors, The uncharacteristic symptoms presented by patients suf
fering from small intestinal malignancies make early diagnosis difficult. T
herefore, especially in patients with lone-standing bowel diseases, maligna
ncy should be considered. Early diagnosis and surgical treatment lead to a
good prognosis as shown by our study.